Travere Therapeutics Inc
NASDAQ:TVTX

Watchlist Manager
Travere Therapeutics Inc Logo
Travere Therapeutics Inc
NASDAQ:TVTX
Watchlist
Price: 17.15 USD -0.17% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Travere Therapeutics Inc?
Write Note

Travere Therapeutics Inc
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Travere Therapeutics Inc
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Travere Therapeutics Inc
NASDAQ:TVTX
PP&E Net
$21.8m
CAGR 3-Years
-15%
CAGR 5-Years
22%
CAGR 10-Years
43%
Abbvie Inc
NYSE:ABBV
PP&E Net
$5.1B
CAGR 3-Years
0%
CAGR 5-Years
10%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
PP&E Net
$5.4B
CAGR 3-Years
2%
CAGR 5-Years
1%
CAGR 10-Years
14%
Amgen Inc
NASDAQ:AMGN
PP&E Net
$6.2B
CAGR 3-Years
7%
CAGR 5-Years
3%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
PP&E Net
$2.5B
CAGR 3-Years
23%
CAGR 5-Years
26%
CAGR 10-Years
13%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
PP&E Net
$4.4B
CAGR 3-Years
9%
CAGR 5-Years
10%
CAGR 10-Years
18%
No Stocks Found

Travere Therapeutics Inc
Glance View

Market Cap
1.3B USD
Industry
Biotechnology

Travere Therapeutics Inc., a biopharmaceutical trailblazer, has carved a niche in the healthcare landscape by focusing on the often-overlooked realm of rare diseases. With a mission to improve the lives of patients grappling with conditions that lack sufficient treatment options, Travere leverages its deep expertise in research, development, and commercialization of therapies. Beyond generic pharmaceuticals, the company's extensive pipeline is filled with innovative treatments, targeting conditions from chronic kidney diseases to rare liver disorders. This strategic emphasis on rare diseases not only exemplifies Travere's commitment to social responsibility but also positions it uniquely within the competitive pharmaceutical sector, where the rarity of these conditions often results in limited competition. The financial lifeline of Travere Therapeutics comes from its ability to navigate the intricate process of bringing drugs from conception to market. Revenue streams are primarily driven by the sales of FDA-approved products, alongside milestone and royalty payments tied to strategic collaborations. The company’s shrewd strategy involves acquiring or licensing promising compounds and utilizing its robust in-house capabilities to carry these assets through clinical trials. This intertwined web of internal development and strategic partnerships creates a sustainable business model. It ensures that as current treatments mature and stabilize their market presence, new pipeline products are continually groomed, keeping revenue streams dynamic while reinforcing their commitment to addressing unmet medical needs.

TVTX Intrinsic Value
29.25 USD
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Travere Therapeutics Inc's PP&E Net?
PP&E Net
21.8m USD

Based on the financial report for Sep 30, 2024, Travere Therapeutics Inc's PP&E Net amounts to 21.8m USD.

What is Travere Therapeutics Inc's PP&E Net growth rate?
PP&E Net CAGR 10Y
43%

Over the last year, the PP&E Net growth was -19%. The average annual PP&E Net growth rates for Travere Therapeutics Inc have been -15% over the past three years , 22% over the past five years , and 43% over the past ten years .

Back to Top